Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02258581 · ClinicalTrials.gov registry record
Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection
A clinical trial, sponsored by Gilead Sciences.
- Terminated
- Registry status
- 241
- Enrollment target
NCT02258581: Clinical Trial study, sponsored by Gilead Sciences.
NCT02258581 is a clinical trial that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 241 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02258581 was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- 241 participants
- Enrollment target
Study Summary
This study will evaluate the long term effects of hepatitis B virus (HBV) treatment on the HBV serologic changes and HBV DNA levels through Week 144. This registry will enroll only individuals who were treated in a Gilead-sponsored trial for chronic hepatitis B (CHB).
Primary Outcome
This endpoint will be measured for participants who are HBsAg positive at baseline.
Interventions
- DRUG Tenofovir disoproxil fumarate (TDF)
- DRUG GS-4774
- DRUG GS-9620
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 241 participants |
| Start Date | 2014-12-09 |
| Est. Completion | 2017-08-14 |
Why NCT02258581 stopped before completion
NCT02258581 is an observational study that tracks outcomes without assigning an intervention. The registered 241 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 3 interventions - of which Tenofovir disoproxil fumarate (TDF) is the first listed.
NCT02258581 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02258581 about?
NCT02258581 is a clinical study titled "Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection". This study will evaluate the long term effects of hepatitis B virus (HBV) treatment on the HBV serologic changes and HBV DNA levels through Week 144. This registry will enroll only individuals who were treated in a Gilead-sponsored trial for chronic hepatitis B (CHB).
What is the current status of trial NCT02258581?
This trial is currently terminated. The enrollment target is 241 participants. The study started on 2014-12-09. Estimated completion is 2017-08-14.
What interventions are being tested in trial NCT02258581?
The interventions under investigation include: Tenofovir disoproxil fumarate (TDF) (DRUG), GS-4774 (DRUG), GS-9620 (DRUG).
Who is sponsoring clinical trial NCT02258581?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01189786 · 241 participants · NA
Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection
- NCT05050383 · 241 participants · NA
DISE: Phenotyping Obstruction Patterns
- NCT05683418 · 241 participants · Phase 1
A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors
- NCT07213791 · 241 participants · Phase 1
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI